Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tyra Biosciences, Inc. (Nasdaq: TYRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing precision medicines targeting FGFR biology through its in-house SNÅP platform. Its SEC filings give investors structured insight into how the company reports its financial condition, pipeline progress and material events related to its FGFR-focused programs.
Among the key documents, Form 8-K current reports are used by Tyra to announce material events such as quarterly financial results and significant clinical milestones. For example, recent 8-K filings reference press releases reporting second and third quarter financial results and an 8-K dated June 30, 2025 describing the first patient dosed in the SURF302 Phase 2 study of TYRA-300 (dabogratinib) in intermediate risk non-muscle invasive bladder cancer. These filings often incorporate press releases by reference, linking financial metrics with updates on studies like SURF302, BEACH301, SURF301, SURF201 and SURF431.
Investors can also use Tyra’s periodic reports (such as the annual report on Form 10-K and subsequent filings referenced in forward-looking statement sections) to understand risk factors, research and development priorities, and the status of clinical-stage candidates including dabogratinib, TYRA-200 and TYRA-430. The company’s filings discuss topics such as trial design, anticipated data readouts, dependence on third parties, regulatory interactions and intellectual property considerations.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that help explain complex sections, highlight key disclosures and point out items of interest such as clinical trial milestones, cash runway commentary and forward-looking statements tied to the SNÅP platform and FGFR-targeted pipeline. Users can quickly review newly posted 8-Ks, 10-Ks and other forms, and connect them to Tyra’s broader narrative in precision oncology and genetically defined skeletal dysplasias.
Tyra Biosciences, Inc. Chief Discovery Officer Daniel Bensen reported planned stock sales. On February 12, 2026, he completed two open-market sales of Tyra Biosciences common stock under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.
Bensen sold 2,128 shares at a weighted average price of $31.5018, with actual prices ranging from $31.02 to $31.75, and 5,872 shares at a weighted average price of $33.3666, with actual prices between $32.98 and $33.85. Following these transactions, he directly owned 146,981 shares of Tyra Biosciences common stock.
Todd Harris filed a Schedule 13G reporting his beneficial ownership of Tyra Biosciences, Inc. common stock. He reports beneficial ownership of 2,814,379 shares of common stock, representing 5.1% of the class, based on 53,706,357 shares outstanding as of December 31, 2025.
The holdings consist of 1,357,168 shares of common stock held directly and 1,457,211 shares underlying stock options that are currently exercisable or become exercisable within 60 days of December 31, 2025. Harris has sole voting and dispositive power over all 2,814,379 reported shares and no shared voting or dispositive power.
Tyra Biosciences, Inc. received an amended Schedule 13G from Canaan investment entities reporting beneficial ownership of its common stock. Canaan XI L.P. directly holds 2,930,444 shares, representing approximately 5.5% of the outstanding common stock, with Canaan Partners XI LLC deemed to beneficially own the same amount as its general partner.
Canaan 2020+ Co-Investment L.P. - Series 7 directly owns 443,885 shares, or about 0.8% of the outstanding shares, with Canaan Partners 2020+ Co-Investment LLC deemed to beneficially own the same. These percentages are based on 53,372,098 shares outstanding as of October 31, 2025. Each reporting person has sole voting and dispositive power over its reported shares.
Daniel Bensen filed a notice of proposed sale of 8,000 shares of TYRA common stock under Rule 144. The planned sale, through Merrill Lynch on the Nasdaq, has an indicated aggregate market value of $262,000, with 53,372,098 shares of the class shown as outstanding.
The shares to be sold were acquired as founders shares from the issuer on 08/28/2018. The filing also lists several recent sales of TYRA common stock by Bensen over the past three months, including transactions in November and December 2025 with gross proceeds up to $1,760,000.
Tyra Biosciences Chief Discovery Officer Bensen Daniel reported preset insider stock sales. On January 12, 2026, he sold 6,983 shares of Tyra Biosciences common stock at a weighted average price of $28.442 and an additional 1,017 shares at a weighted average price of $29.0808, both listed as open-market sales. These trades were carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to pre-schedule transactions. After these sales, Daniel beneficially owned 154,981 shares of Tyra Biosciences common stock in direct ownership.
Tyra Biosciences shareholder Daniel Bensen has filed a Form 144 indicating an intent to sell additional common shares. The notice covers 8,000 shares of common stock to be sold through Merrill Lynch, with an approximate sale date of 01/12/2026 on Nasdaq. These 8,000 shares were acquired on 08/28/2018 as founder shares directly from the issuer.
The filing also lists recent sales by Bensen over the prior three months. Transactions include 1,111 shares on 11/13/2025 for gross proceeds of 17,000, 110,228 shares on 11/14/2025 for 1,760,000, 20,072 shares on 11/17/2025 for 320,000, 75,633 shares on 11/18/2025 for 1,200,000, 49,956 shares on 11/19/2025 for 815,000, and 8,000 shares on 12/12/2025 for 180,000. The form includes the standard representation that the seller is not aware of undisclosed material adverse information about the company.
Tyra Biosciences, Inc. reported that an officer serving as Chief Discovery Officer sold 8,000 shares of common stock on 12/12/2025. The transaction was coded as a sale and executed at a weighted average price of $22.6449, with individual sale prices ranging from $22.06 to $23.03.
The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024. Following this transaction, the officer beneficially owns 162,981 shares of Tyra Biosciences common stock, held directly.
Tyra Biosciences, Inc. (TYRA)11/21/2025, the fund sold 246,871 shares of common stock in an open-market transaction coded as a sale. The shares were sold under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2025.
The filing states a weighted average sale price of $20.2536 per share, with individual sale prices ranging from $20.25 to $21.24. After this transaction, 3,833,425 shares of Tyra Biosciences common stock are reported as beneficially owned indirectly through the fund. The reporting person notes that beneficial ownership is disclaimed beyond his pecuniary interest in those shares.
Tyra Biosciences, Inc. reported insider stock sales by its Chief Operating Officer. The executive filed a Form 4 showing open-market sales of Tyra common stock on 11/18/2025 and 11/19/2025. On the first date, the officer sold 75,633 shares of common stock at a weighted average price of $16.0727, leaving 220,937 shares beneficially owned directly afterward. On the second date, the officer sold an additional 49,956 shares at a weighted average price of $16.3203, and reported direct beneficial ownership of 170,981 shares following that transaction. The filing notes that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
Tyra Biosciences, Inc. Chief Operating Officer, listed as an officer and sole reporting person, reported multiple open-market sales of common stock. On 11/13/2025, the COO sold 1,111 shares at a weighted average price of $16.0036, leaving 426,870 shares beneficially owned. On 11/14/2025, an additional 110,228 shares were sold at a weighted average price of $16.0167, reducing beneficial ownership to 316,642 shares. On 11/17/2025, the COO reported sales of 18,572 shares at a weighted average price of $16.1098 and 1,500 shares at a weighted average price of $17.0713, resulting in 296,570 shares of common stock beneficially owned following the transactions.
The filing states that all reported sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, and that the disclosed prices represent weighted averages over multiple trades within specified price ranges.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
